Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Jeffrey A. Morgan, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Senior Physician
  • Instructor in Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bone sarcomas
  • Developmental therapeutics
  • Gastrointestinal stromal tumors (GIST)
  • Soft tissue sarcoma

Contact Information

  • Appointments617-632-5122
  • Office Phone Number617-632-5204
  • Fax617-632-3408

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1993
  • Medical Oncology, 1999

Fellowship:

  • Brigham and Women's Hospital, Hematology & Oncology
  • Brigham and Women's Hospital, Pathology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Research

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
View in: PubMed

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290.
View in: PubMed

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
View in: PubMed

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30.
View in: PubMed

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.
View in: PubMed

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6.
View in: PubMed

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43.
View in: PubMed

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9.
View in: PubMed

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
View in: PubMed

Imaging features of bone metastases in patients with gastrointestinal stromal tumors. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):391-6.
View in: PubMed

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012; 7(2):e26331.
View in: PubMed

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):871-9.
View in: PubMed

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10; 28(5):835-40.
View in: PubMed

Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15.
View in: PubMed

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6232-40.
View in: PubMed

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
View in: PubMed

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009 Sep 15; 15(18):5910-6.
View in: PubMed

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24.
View in: PubMed

Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10.
View in: PubMed

Epithelioid angiosarcoma of the uterus: a review of management. Arch Gynecol Obstet. 2008 Nov; 278(5):401-4.
View in: PubMed

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
View in: PubMed

Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec; 14(12):3534-41.
View in: PubMed

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
View in: PubMed

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 01; 109(9):1863-9.
View in: PubMed

Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol. 2007 Mar; 23(2):149-58.
View in: PubMed

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 07; 145(9):660-4.
View in: PubMed

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14; 368(9544):1329-38.
View in: PubMed

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31.
View in: PubMed

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 01; 101(5):934-9.
View in: PubMed

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 01; 94(1):97-103.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1212
Boston, MA 02215
Get Directions

Ratings

Top